GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHF) » Definitions » Debt-to-EBITDA

Melodiol Global Health (Melodiol Global Health) Debt-to-EBITDA : -1.81 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Melodiol Global Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.40 Mil. Melodiol Global Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil. Melodiol Global Health's annualized EBITDA for the quarter that ended in Dec. 2023 was $-3.56 Mil. Melodiol Global Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Melodiol Global Health's Debt-to-EBITDA or its related term are showing as below:

COPHF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.39   Med: -0.22   Max: -0.15
Current: -0.39

During the past 8 years, the highest Debt-to-EBITDA Ratio of Melodiol Global Health was -0.15. The lowest was -0.39. And the median was -0.22.

COPHF's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.695 vs COPHF: -0.39

Melodiol Global Health Debt-to-EBITDA Historical Data

The historical data trend for Melodiol Global Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Debt-to-EBITDA Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.25 -0.15 - -0.22 -0.38

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.14 -0.25 -1.81

Competitive Comparison of Melodiol Global Health's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Melodiol Global Health's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Debt-to-EBITDA falls into.



Melodiol Global Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Melodiol Global Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.4 + 0.056) / -16.839
=-0.38

Melodiol Global Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.4 + 0.056) / -3.56
=-1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Melodiol Global Health  (OTCPK:COPHF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Melodiol Global Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (Melodiol Global Health) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire 02-07-2022